Explore
For Enterprise
Join for Free
Log In

Arts and Humanities
Business
Computer Science
Data Science
Information Technology
Health
Math and Logic
Personal Development
Physical Science and Engineering
Social Sciences
Language Learning
Degrees
Certificates

Explore all of Coursera

Browse
Search
For Enterprise
Log In
Join for Free

Immunotherapy for Non-Small Cell Lung Cancer

Loading...

Thoracic Oncology

University of Michigan

4.9 (143 ratings) | 6.6K Students Enrolled

Thoracic malignancies are major, global health problems. Lung cancer is the most common cancer and cause of cancer death in the world, with more than 1.5 million deaths per year. More Americans will die from lung cancer each year (approximately 159,480) than from colon, breast, pancreatic, and prostate cancer combined (approximately 158,630), the next most common causes of cancer death. Esophageal cancer is the 6th most common cause of cancer deaths worldwide, and the 4th most common cause in developing nations. This course will provide a comprehensive, multidisciplinary introduction to state of the art approaches in the care of patients with thoracic malignancies, including various types of lung cancers and esophageal cancers. Didactic material will cover epidemiology, screening and diagnosis, staging, imaging, radiation therapy, systemic therapy, surgery, psychiatry, and patient support topics. This is an on-demand course with integrated learning units that are focused on specific topics. Each unit contains several video lectures with interactive questions and is followed by a short quiz. Prerequisites: None required although basic medical training in some field related to thoracic oncology would be helpful.

Reviews

4.9 (143 ratings)

5 stars
132 ratings
4 stars
11 ratings

RN

Apr 01, 2019

Fantastic course. Highly recommended for new Thoracic trainees to go through this at the beginning of their training.

SS

Jul 18, 2017

Great course with great info to be part of. Enjoyed..!! Thank you Michigan and professors.

From the lesson

Non-Small Cell Lung Cancer and Tracheal Cancer: Therapeutics

After reviewing this unit, the learner will understand basic principles regarding:

Introduction to Radiation Therapy13:10

Definitive Radiation Therapy For Stage I NSCLC13:00

Definitive Radiation Therapy For Locally Advanced NSCLC21:33

Palliative Radiation Therapy For Metastatic Lung Cancer17:45

Stereotactic Body Radiation Therapy (SBRT) For Oligometastatic Lung Cancer10:28

Adjuvant Therapy for Non-Small Cell Lung Cancer14:58

Combined Modality Therapy For Locally Advanced Non-Small Cell Lung Cancer17:01

Overview of Stage IV Non-Small Cell Lung Cancer14:05

Chemotherapy for Stage IV Non-Small Cell Lung Cancer30:23

Immunotherapy for Non-Small Cell Lung Cancer19:03

Molecularly Targeted Therapy for Non-Small Cell Lung Cancer28:03

FDG-PET Imaging of Non-Small Cell Lung Cancer: Treatment Response Monitoring9:52

Early Stage: Surgery - Lung Resection - Wedge, Segmentectomy, Lobectomy15:01

Complex Lung Resection: Sleeve Lobectomy and Pneumonectomy8:49

Thoracotomy Versus Minimally Invasive Approaches for Lung Cancer Resection11:39

Palliative Surgery For Stage IV Lung Cancer - Tracheal and Pleural Disease9:36

Chest Wall Resection16:55

Metastasectomy of Cancer Spread to the Lung7:06

Peri-Operative Evaluation and Fitness6:41

Complications After Lung Cancer Surgery20:06

Taught By

Dr. Leslie Eisenbud Quint
Course Co-director, Professor of Radiology and Professor of Surgery, Section of Thoracic Surgery
Dr. Rishindra Reddy
Course Co-director, Assistant Professor of Surgery, Section of Thoracic Surgery
Dr. Gregory Kalemkerian
Course Co-director, Professor of Medicine, Division of Hematology/Oncology
Thoracic Oncology team at the University of Michigan

Transcript

I'm Greg Kalemkerian, Professor of Medicine in Division of

Hematology Oncology at the University of Michigan.

This is lecture is going to cover the use of immunotherapy for

people with stage IV non-small cell lung cancer.

The objectives of the talk are to review the mechanism of activity of immune

checkpoint inhibition and to review the role of immunotherapy as first-line or

subsequent therapy in people with stage IV non-small cell.

Cancers can utilize multiple mechanisms, including the PDI/ PD-LI pathway,

to evade normal immune surveillance.

PDI and PD-LI inhibitors, the immune checkpoint inhibitors

can block the local inactivation of cytotoxic T-cells.

Immune checkpoint inhibitors can induce durable responses and

improve survival in people with advanced non-small cell lung cancer.

Our pre-lecture question is that a 72 year-old woman presents with dyspnea and

right hip pain.

She's ambulatory and able to care for herself with a performance status of one.

Her pain is controlled with narcotics.

CT scan shows a large left upper lobe mass, multiple smaller lung nodules,

enlarged bilateral mediastinal lymph nodes and numerous lytic bone metastases.

Biopsy of the lung mass reveals poorly differentiated squamous cell

with PD-L1 expression in 70% of tumor cells.

What is the most appropriate further management?

Carboplatin and paclitaxel?

Carboplatin, paclitaxel and bevacizumab?

Erlotnib, or pembrolizumab?

Let's go through the lecture and

we'll come back to the answer to question at the end of the talk.

For many years, the field of immunotherapy sought to find deficits

within the immune system that would allow a cancer to develop and

not be recognized by the patient's immune system as abnormal.

However, such deficits were never fully identified because

in actuality the body does recognize the cancer as abnormal.

The immune system recognizes abnormal mutant proteins within the cancer and

can utilize its usual mechanism of dendritic cell presentation to T-cells in

order to develop cytotoxic T-cells that are primed to attack the tumor cells.

Now the tumor can use a variety of mechanisms in order to avoid detection and

killing by cytotoxic T-cells that are primed to attack it.

One of those mechanisms is the PD-LI, PD-I pathway as noted here.

PD-LI is a ligand that is expressed

by tumor cells that can bind to the PD-I receptor

on the T-cells, thereby, inactivating this T-cell.

So now the T-cell will not penetrate into the tumor, and

will not kill the tumor cell.

So in essence, the tumor cells are co-opting

a normal tolerance system utilized by the immune system in order to get

the body to recognize the cancer as self and not to kill it.

Now what's been developed are a number of monoclonal antibodies

including Nivolumab that combine to either the PD-I receptor, or

PD-LI1 being made by the tumor and thereby inhibit the binding

of PD-LI to PD-I, and inhibit the inactivation of T-cells so

that the T-cells remain active and can thereby kill the tumor cells.

So the immunotherapy with checkpoint inhibitors that we are utilizing now

is an indirect mechanism to kill cancer cells by allowing the the immune

system to not only recognize them, but also remain active in killing them.

Initially, immunotherapy was evaluated as subsequent therapy after

chemotherapy had failed in people with non-small cell lung cancer.

The Checkmate 017 trial was one of first studies to evaluate the use of

immunotherapy with Nivolumab and anti PD-I monoclonal

antibody in patients with relapsed non-small cell lung cancer,

who had had one prior regimen of platinum-containing chemotherapy.

This study randomized people to receive either Nivolumab or Docetaxel,

which is standard second-line chemotherapy.

And we see that the response rates were significantly higher in people receiving

Nivolumab than receiving Docetaxel, and overall survival was

significantly improved from a median of six months up to nine months.

And a one year overall survival from 24% up to 42% with single agent immunotherapy.

This is called a swimmer's plot in which we look at people who responded

to treatment, here with Nivolumab, here with Docetaxel, and the horizontal bar

is an individual patient and the length of the bar designates the duration of time

in weeks that the response duration occurred.

And we see that those who received Nivolumab had an improvement in

the duration of response versus those who had Docetaxel.

In evaluating whether or not there's a bio-marker that can predict who's going to

benefit the most from the Nivolumab, the study looked at people with

a variety of different cutoffs from 1% to 5% to 10% PD-L1

tumor cell expression and did not find any significant difference in the ability

of people to benefit from treatment based on PD-LI expression levels.

So the results of that initial Checkpoint 017 trial

are up on top here as we already went through.

A similar study was done in non-squamous,

non-small cell lung cancer looking at Nivolumab versus Docetaxel,

and this study demonstrated an improvement in response, and

a similar improvement in overall survival with Nivolumab over Docetaxel.

Thereby establishing single agent immunotherapy

as a standard second line treatment after first line chemotherapy.

The Keynote 10 trial was a similar trial,

that evaluated Pembrolisomab, another anti PD-I monoclonal antibody

versus Docetaxel in people who relapse small cell lung cancer.

This study included patients with a variety of histologic subtypes,

all of whom had PD-LI expression greater than 1%.

Patients received one of two different doses of Pembrolizuma or Docetaxel,

and looking at the overall patient population which is a large population

with more than 1% expression of PD-LI, we see an improvement in

response rate as well as an improvement in overall survival with Pembrolizumab.

And then we look at only a population with very high PD-LI tumorous cell expression

of greater than 50% of tumor cells, we see that there's an even greater benefit

with regard to response rate and with regard to survival.

So in this situation with Pembrolizumab, it appears that PD-LI expression

can be a useful bio-marker to predict the degree of benefit.

This can be seen on this graphic slide, looking at the overall population

with the two Pembrolizumab arms being superior to Docetaxel, but

a bigger difference seen here with the Pembrolizumab arms versus Docetaxel when

we're amplifying the population for very high P-DLI level expressions.

Looking at the data with regard to PD-LI expression a little differently,

this is data from the phase I dose expansion with Pembrolizumab in non small

cell lung cancer.

Looking at different levels of PD-LI expression all on the same curve,

looking at progression-free survival and overall survival.

With the low expression levels here, and

patients with high expression levels up above, greater than 50%,

and we see that there's a significant improvement in survival for

people with higher levels of PD-LI expression.

Another important question that has arisen with regard to immunotherapy and

lung cancer is what is the potential benefit for

people who have driver mutation tumors?

So tumors that harbor driver mutations in EGFR or ALK.

And this was a retrospective analysis from Boston

that looked at 22 patients with EGFR-mutant lung cancer,

6 patients with ALK positive lung cancer, versus people

who had ALK and EGFR wild type tumors.

All of these people had received single agent anti PDI or PD-LI therapy.

And what was demonstrated was that the overall response rate was lower in

people who had EGFR or ALK mutant tumors at about 4% response rate

versus those who were wild type with about a 23% response rate.

This also tracked with smoking status where there was a 4% rate response

in never or light smokers and a 20% response rate in heavy smokers.

Again, suggesting that the higher mutational burden found in smokers

as well as in people who are EGFR and

ALK wild type may help drive immune recognition and immune response.

There was also a slightly better progression free survival

in those who had EGFR or ALK negative tumors.

So the low activity of PDI or PD=LI inhibitors in EGFR-mutated or

ALK rearranged or ROSI rearranged non-small cell lung cancer

tells us that chemotherapy is probably a better second line option

than immunotherapy in people with known driver mutations.

After the demonstration of benefit of immunotherapy as subsequent

treatment in non small cell lung cancer, studies were done

evaluating first line treatment with an immunotherapeutic action.

The Keynote 024 study evaluated 1st-line Pembrolizumab vs chemotherapy

in people with untreated stage IV non small cell who had high level of

PD-LI expression by immunochemistry with over 50% of tumor cells expressing PD-LI.

This study was reported with relatively short median follow up of 11 months.

But as we can see, it does demonstrate a significant improvement in response rate,

up to 45% response rate in people Pembrolizumab as well as an improvement

in, a significant improvement in progression free, and overall survival.

Admittedly, with short follow up, but clearly showing us that in people who have

high levels of PD-LI expression, single agent Pembrolizumab does appear

to be superior to chemotherapy in terms of response and survival.

Importantly, this trial did not differentiate patients based on histology

and utilized a variety of different chemotherapeutic agents

depending on histologic subtypes and investigator preference.

Graphically, we see that both progression free survival and

overall survival are significantly improved with single agent Pembrolizumab

versus chemotherapy in people with high levels of PD-LI tumor expression.

There is no free lunch so all treatments have potential toxicities.

If we look at this table, we see that for

any level of toxicity, the toxicity was a bit lower for

the Pembrolizumab alone group with grade three,

four toxicities lower for the immunotherapy.

Approximately 20% of people with immunotherapy

had a serious adverse event of grade three or

higher with about a 5% treatment related death rate,

similar to that of chemotherapy.

Now obviously with immunotherapy, we have to be concerned

about immune-mediated side effects such as hypothyroidism and pneumonitis.

And we can see that as would make sense, the rate of these events

is greater than with chemotherapy with about 10% of people

having a significant grade 3 or greater immune mediate event.

And usually these types of events would

require a discontinuation of the immunotherapeutic agent and

initiation of steroid therapy to decrease symptoms.

So recently, the Keynote-189 trial looked at chemotherapy with or

without Pembrolizumab, the anti-PD-I monoclonal antibody.

This study looked at a large number, over 600 people with untreated, advanced,

non-squamous, non-small cell lung cancer who did not have an EGFR or ALK mutation.

And randomized them to get either platinum and Pemetrexed followed by Pemetrexed as

a standard treatment arm versus platinum Pemetrexed

plus Pembrolizumab followed by Pemetrexed plus Pembrolizumab.

And we see that there was an improvement in response rate,

an improvement in progression free survival and a significant improvement in

overall survival with the addition of Pembrolizumab.

Suggesting that the treatment with three drugs, chemo,

plus Pembrolizumab was superior to treatment with chemotherapy

alone in patients with non-squamous, non small scale lung cancer.

Importantly, this study included people with a variety of levels of

PD-LI expression, on the left we see PD-LI expression less than 1%,

middle is 1% to 49%.

On the left, greater than 50% and there's an improvement in survival

with Pembrolizumab in all of these sub classifications based on PD-LI expression

with the improvement highest in those with the higher all level of PD-LI expression.

But all patients seemed to potentially benefit.

Again, there are always potential side effects as we see here,

looking at the events of interest which are mainly the itises,

the inflammatory conditions brought on by stimulation of the immune system

to recognize self as abnormal.

With about 10% of people having a grade three or

greater immune mediated toxicity including lumenitis,

hyperthyroidism, and nephritis as specific side effects of interest.

So what do we know about immunotherapy with the PDI,

PD-LI inhibitors in non-small cell lung cancer?

As first line treatment, Pembrolizumab is superior to chemotherapy in patients with

high PD-LI tumor cell expression, greater than 50%.

Chemotherapy plus Pembrolizumab is superior to chemo alone in non-squamous

non-small cell lung cancer regardless of PD-LI expression level.

As second line therapy, Nivolumab, Pembrolizumab, and

Atezolizumab, Atezolizumab is a PD-LI targeted monoclonal antibody,

are all superior to chemotherapy.

Nivolumab and Atezolizumab are FDA approved

regardless of PD-LI expression whereas Pembrolizumab is FDA approved for

people with PD-LI greater than or equal to 1% of tumor cells.

So let's return to our question of a 72-old-year woman with shortness of breath

and hip pain who is up and around and doing well with a performance status of 1.

Her pain is controlled.

CT scan shows the left upper lobe mass,

lung nodules, mediastinal lymph nodes, and many bony metastases.

Biopsy showed a poorly differentiated squamous cell with a high PD-LI

expression in 70% of tumor cells.

What is the most appropriate further management?

Carboplatin and Paclitaxel, Carboplatin, Paclitaxel and

Bevacizumab, or Erlotinib, or Pembrolizumab?

And this woman who has good functional status and

squamous cell with a high PD-LI expression level, the most appropriate treatment

would be single agent Pembrolizumab as noted in this question.

Another option would be a combination of chemotherapy plus Pembrolizumab,

though the Keynote-189 trial did not specifically answer the question

of whether Pembrolizumab alone or chemo plus Pembrolizumab is

more beneficial in people with high levels of PD-LI expression.

So take home points from this lecture,

PD-LI pathway suppresses local T-cell surveillance of tumors.

PDI, PD-LI inhibitors allow local activation of cytotoxic T-cells and

are active in non small cell with durable responses.

The activity correlates with tumor PD-LI expression, and these

drugs are basically well tolerated, but we do have to be aware of systemic autoimmune

toxicities that can cause significant declines in people's quality of life that

need to be recognized quickly in order to try and maximize control of symptoms.

Thank you.

Explore our Catalog

Join for free and get personalized recommendations, updates and offers.

Coursera provides universal access to the world’s best education, partnering with top universities and organizations to offer courses online.

© 2019 Coursera Inc. All rights reserved.

Download on the App Store

Get it on Google Play

Coursera
About
Leadership
Careers
Catalog
Certificates
MasterTrack™ Certificates
Degrees
For Enterprise
For Government

Community
Learners
Partners
Developers
Beta Testers
Translators

Connect
Blog
Facebook
LinkedIn
Twitter
Instagram
YouTube
Tech Blog

More
Terms
Privacy
Help
Accessibility
Press
Contact
Directory
Affiliates